Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials.

Mahindra, Amit; Janha, Omar; Mapesa, Kopano; Sanchez-Azqueta, Ana; Alam, Mahmood M; Amambua-Ngwa, Alfred; Nwakanma, Davis C; Tobin, Andrew B; Jamieson, Andrew G; (2020) Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. Journal of medicinal chemistry, 63 (17). pp. 9300-9315. ISSN 1520-4804 DOI: https://doi.org/10.1021/acs.jmedchem.0c00451

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1021/acs.jmedchem.0c00451

Abstract

Item Type Article
Faculty and Department MRC Gambia > GM-Vaccinology Theme
PubMed ID 32787140
Elements ID 151266

Share

Download

Restricted to: Repository staff only

Request a copy

Filename: Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

[img]

Downloads

View details

Metrics & Citations


Google Scholar